| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Methotrexate | CTRPv2 | pan-cancer | AAC | -0.074 | 0.05 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.095 | 0.05 |
| mRNA | GDC-0449 | GDSC1000 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | BRD-K90370028 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.05 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.05 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | -0.07 | 0.05 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.062 | 0.06 |
| mRNA | tretinoin:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.067 | 0.06 |
| mRNA | Erlotinib | FIMM | pan-cancer | AAC | 0.31 | 0.06 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | -0.069 | 0.06 |